meta|evidence oncology

Living systematic review and meta-analysis

breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA) 2
es-BC - HR-positive - 1st line (L1) 1
la/mBC - HR positive 2
la/mBC - HR positive - (neo)adjuvant (NA) 3
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1) 13
la/mBC - HR positive - L1 - PIK3CA mutant 1
la/mBC - HR-positive - 2nd line (L2) 20
la/mBC - HR positive - L2 - all population 1
la/mBC - HR positive - L2 - PIK3CA mutant 1

phosphoinositide 3-kinase (PI3K) inhibitor
taselisib based treatment
taselisib plus letrozole

versus all
vs endocrine therapy
vs letrozole

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -